Mirati Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (10)

Latest Posts

About This Stock More About This Stock
Piper Says Mirati Now 'Prime' Biotech Takeout Candidate, Boosts Target
Article By: The Fly
Thursday, November 5, 2020 5:37 AM EDT
Piper Sandler analyst Tyler Van Buren raised the firm's price target on Mirati Therapeutics to $260 from $210 and keeps an Overweight rating on the shares.
In this article: MRTX
Read
Mirati Therapeutics - All Time High
Article By: Jim Van Meerten
Thursday, October 29, 2020 2:14 PM EDT
Revenue expected to grow 566.90% next year.
In this article: MRTX
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA
Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Mirati Therapeutics - Chart Of The Day
Article By: Jim Van Meerten
Monday, March 12, 2018 6:51 PM EDT
Since the Trend Spotter signaled a buy on 1/10 the stock gained 60.69%.
In this article: MRTX
Read
Week In Review: Sinocare Eyes $4 Billion Deal For J&J Diabetes Device Business
Article By: ChinaBio® Today
Saturday, January 20, 2018 5:34 PM EDT
Sinocare, a diabetes company based in Changsha, may bid as much as $4 billion to acquire Johnson & Johnson's diabetes medical device subsidiaries. With falling revenues, some of J&J's diabetes-focused companies are exiting from the US market.
In this article: JNJ, LLY, CELG, BGNE, MRTX, AMRN
Read

Latest Tweets for $MRTX

No tweets yet!